Molecular insights, particularly the duplication of the T gene (brachyury) and alterations in CDKN2A/B, EGFR, and chromatin remodeling genes, have paved the way for targeted therapies, highlighting the potential of personalized medicine in improving chordoma treatment paradigms and reserving aggressive surgery for only the most advanced cases [14,15]. Here, CDKN2A is linked to chordoma.